Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
Vienna General Hospital · The University of Sydney · +7 more institutions
Abstract
The intent-to-treat population comprised 634 patients from the original two-arm portion of the study, plus an additional 1,400 patients after the start of the amended 2 x 2 design, for a total of 2,034 patients. The median PFS was 8.0 months in the pooled XELOX-containing arms versus 8.5 months in the FOLFOX-4-containing arms (hazard ratio [HR], 1.04; 97.5% CI, 0.93 to 1.16). The median overall survival was 19.8 months with XELOX versus 19.6 months with FOLFOX-4 (HR, 0.99; 97.5% CI, 0.88 to 1.12). FOLFOX-4 was associated with more grade 3/4 neutropenia/granulocytopenia and febrile neutropenia than XELOX, and XELOX with more grade 3 diarrhea and grade 3 hand-foot syndrome than FOLFOX-4.
XELOX is noninferior to FOLFOX-4 as a first-line treatment for MCRC, and may be considered as a routine treatment option for appropriate patients.
Citation impact
- FWCI
- 33.63
- Percentile
- 100%
- References
- 16
Authors
13- JCJim CassidyCorresponding
Vienna General Hospital
- SCStephen Clarke
The University of Sydney, Memorial Sloan Kettering Cancer Center, Tel Aviv Sourasky Medical Center, Beatson West of Scotland Cancer Centre, Vienna General Hospital, Chang Gung Memorial Hospital, Russian Cancer Research Center NN Blokhin, Medical University of Vienna, Switch
- EDEduardo Díaz‐Rubio
The University of Sydney, Memorial Sloan Kettering Cancer Center, Tel Aviv Sourasky Medical Center, Beatson West of Scotland Cancer Centre, Vienna General Hospital, Chang Gung Memorial Hospital, Russian Cancer Research Center NN Blokhin, Medical University of Vienna, Switch
- WSWerner Scheithauer
The University of Sydney, Memorial Sloan Kettering Cancer Center, Tel Aviv Sourasky Medical Center, Beatson West of Scotland Cancer Centre, Vienna General Hospital, Chang Gung Memorial Hospital, Russian Cancer Research Center NN Blokhin, Medical University of Vienna, Switch
- AFArié Figer
The University of Sydney, Memorial Sloan Kettering Cancer Center, Tel Aviv Sourasky Medical Center, Beatson West of Scotland Cancer Centre, Vienna General Hospital, Chang Gung Memorial Hospital, Russian Cancer Research Center NN Blokhin, Medical University of Vienna, Switch
Topics & keywords
- FOLFOX
- Oxaliplatin
- Medicine
- Folinic acid
- Bevacizumab
- Capecitabine
- Internal medicine
- Colorectal cancer
- Good health and well-being